UNSPSC 51382705: Sulindac sulfone

This classification denotes a cyclooxygenase inhibitor with the molecular formula C20H17FO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K619IIG2R9, chemically known as 1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (1z)-, but more generally known as sulindac sulfone, which bears US NIH Compound Identifier 5472495. European Medicines Agency schedules sulindac sulfone or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10744MIG.

Most nations, for tariff purposes, schedule sulindac sulfone under HS 29309085. SMILES: CC\1=C(C2CC(CCC2/C1=C\C3CCC(CC3)S(=O)(=O)C)F)CC(=O)O.

UNSPSC 51382705 Sulindac sulfone is a Commodity code, but the recent state and local procurement activity tagged under it does not align with the code's pharmaceutical scope—recent opportunities center on naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution through cooperative purchasing, none of which are sulindac sulfone. The code shows minimal relevant recent activity. State and local health agencies, including county health departments and state health and human services commissions, are the primary issuing bodies driving pharmaceutical procurement in this space, though the sourced opportunities do not specifically target sulindac sulfone as a line item.

Activity appears concentrated in Florida and Texas, with cooperative purchasing vehicles like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multi-state participation including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (naloxone and drug deactivation systems, IFB posted June 30, 2026, due July 26, 2023), the Texas Health and Human Services Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's S1070000015802 for generic multi-source pharmaceuticals and OTC products (RFP posted January 20, 2026, due March 26, 2026). Without recent solicitations specifically naming sulindac sulfone, pursue this code only if your firm supplies generic or branded sulindac sulfone through established pharmaceutical distribution channels or wholesaler relationships; otherwise, monitor for future health-agency RFPs that may include it within broader pharmaceutical procurement.